Granite Bio

Granite Bio is a private, pre-revenue biotech developing novel antibody therapies for inflammatory, autoimmune, and fibrotic diseases. Its lead asset, GRT-001, is a Phase 1b 'innate Rituximab' targeting pro-inflammatory monocytes, while GRT-002 is a preclinical anti-IL-3 program. The company is backed by top-tier venture capital firms and led by a team with deep industry experience in immunology and drug development.

Platform for developing first-in-class therapeutic antibodies that selectively deplete pathogenic immune cells via ADCC/ADCP, informed by proprietary patient profiling to identify novel disease biology nodes.

Granite Bio competes in the crowded immunology and fibrosis space against large pharma (e.g., AbbVie, Johnson & Johnson, Roche) and numerous biotechs. Its differentiation lies in targeting novel biology nodes (e.g., pro-inflammatory monocytes, IL-3) with cell-depleting antibodies, a mechanism less explored in inflammation compared to cytokine blockade.